Hoffmann-La Roche Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$96.0M
Doctors Paid
608
Transactions
9,381
2024 Total
$9.1M
Payment Breakdown by Category
Research$94.8M (98.8%)
Consulting$913,272 (1.0%)
Travel$141,778 (0.1%)
Food & Beverage$76,677 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $94.8M | 8,083 | 98.8% |
| Consulting Fee | $913,272 | 273 | 1.0% |
| Travel and Lodging | $141,778 | 316 | 0.1% |
| Food and Beverage | $76,677 | 639 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,343 | 35 | 0.1% |
| Education | $1,300 | 34 | 0.0% |
| Grant | $678.60 | 1 | 0.0% |
Payments by Type
Research
$94.8M
8,083 transactions
General
$1.2M
1,298 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | $18.6M | 0 | 550 |
| ACUTE SCHIZOPHRENIA STUDY | $14.2M | 0 | 418 |
| MORPHEUS BREAST | $3.6M | 0 | 291 |
| AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE | $3.2M | 0 | 300 |
| RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | $3.1M | 0 | 121 |
| Coated tablet bioequivalence study | $2.9M | 0 | 54 |
| Acute Schizophrenia study | $2.7M | 0 | 143 |
| Morpheus Breast Cancer | $2.4M | 0 | 238 |
| PH IIB OF ASTEGOLIMAB IN COPD | $2.2M | 0 | 413 |
| MORPHEUS CRC | $2.1M | 0 | 144 |
| Morpheus Breast | $1.9M | 0 | 182 |
| MORPHEUS TNBC | $1.9M | 0 | 229 |
| OPERETTA II Ocrelizumab Pediatric Phase III study | $1.8M | 0 | 200 |
| TAAR1 4 FOR NEGATIVE SYMPTOMS | $1.7M | 1 | 336 |
| PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | $1.7M | 0 | 118 |
| BLU667 1101 ARROW ongoing | $1.6M | 0 | 184 |
| A PHASE 1B STUDY EVALUATING THE EFFICACY SAFETY OF ATEZOLIZUMAB AND COTELLIC IN 2L BRAFWT MELANOMA | $1.4M | 0 | 200 |
| Morpheus Melanoma | $1.3M | 0 | 82 |
| ABT 199 GDC 0199 IN 1L DLBCL | $1.3M | 1 | 70 |
| A PHASE IB OPEN LABEL STUDY EVALUATING THE SAFETY TOLERABILITY AND PK OF COBIMETINIB | $1.3M | 0 | 81 |
| A PHASE IB OPEN LABEL STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF COBIMETINIB | $1.3M | 0 | 76 |
| TAAR1 4 for negative symptoms | $1.2M | 1 | 247 |
| PHASE 3 R R CLL WITH GDC0199 BR | $1.1M | 9 | 166 |
| RANDOMIZED DB DD ACTIVE COMPARATOR STUDY OF RITUXIMAB SAFETY EFFICACY IN PEMPHIGUS VULGARIS | $981,357 | 0 | 157 |
| A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | $840,988 | 1 | 180 |
| STUDY TO ASSESS EFFICACY SAFETY AND TOLERABILITY IN AMBULATORY BOYS WITH DMD | $802,244 | 0 | 75 |
| ASCENDING DOSE STUDY IN BOYS WITH DMD | $755,658 | 0 | 41 |
| RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS | $752,875 | 0 | 66 |
| Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | $690,487 | 0 | 132 |
| Double blind study to determine efficacy of ASO Factor B in IgAN | $689,890 | 0 | 154 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Scott Newsome, D.o, D.O | Neurology | Baltimore, MD | $25,449 | $0 |
| Dr. John Kitchens, M.d, M.D | Ophthalmology | Lexington, KY | $22,994 | $0 |
| Dr. Wb Younger, Md, MD | Hematology & Oncology | Boston, MA | $22,525 | $0 |
| Dr. Sunir Garg, M.d, M.D | Ophthalmology | Plymouth Meeting, PA | $21,756 | $0 |
| John Stone, M.d, M.D | Internal Medicine | Boston, MA | $21,394 | $0 |
| Brian Weinshenker, M.d, M.D | Neurology | Charlottesville, VA | $20,330 | $0 |
| Dr. Claudia Chiriboga, M.d, M.D | Neurology with Special Qualifications in Child Neurology | New York, NY | $20,248 | $0 |
| David Almeida, Md, Mba, Phd, MD, MBA, PHD | Retina Specialist | Erie, PA | $20,092 | $0 |
| Karen Shore, M.d, M.D | Diagnostic Radiology | Boston, MA | $20,040 | $0 |
| Talia Kaden, M.d, M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $19,151 | $0 |
| Dr. Ahmed Kaseb, Md, MD | Medical Oncology | Detroit, MI | $18,605 | $0 |
| Steven Pipe, Md, MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $16,553 | $0 |
| Michael Ip, Md, MD | Ophthalmology | Pasadena, CA | $15,700 | $0 |
| Dr. Lawrence Holder, M.d, M.D | Diagnostic Radiology | Jacksonville, FL | $15,660 | $0 |
| Murtaza Adam, Md, MD | Ophthalmology | Parker, CO | $14,938 | $0 |
| Mr. Harit Bhatt, M.d, M.D | Retina Specialist | Oak Forest, IL | $14,255 | $0 |
| Dr. Katherine Talcott, M.d, M.D | Internal Medicine | Cleveland, OH | $14,082 | $0 |
| Syed Anees, M.d, M.D | Pulmonary Disease | Findlay, OH | $13,115 | $0 |
| Dr. Guy Young, M.d, M.D | Pediatric Hematology-Oncology | Bozeman, MT | $12,969 | $0 |
| Srinivas Sadda, Md, MD | Ophthalmology | Pasadena, CA | $12,588 | $0 |
| Dr. Arjun Balar, Md, MD | Medical Oncology | New York, NY | $10,296 | $0 |
| Dr. Crystal Proud, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Norfolk, VA | $9,656 | $0 |
| Dr. Rebecca Kruse-Jarres, M.d, M.D | Hematology & Oncology | Seattle, WA | $9,168 | $0 |
| Stephen Liu, Md, MD | Medical Oncology | Los Angeles, CA | $9,120 | $0 |
| Paul Noble, Md, MD | Critical Care Medicine | West Hollywood, CA | $9,120 | $0 |
About Hoffmann-La Roche Limited
Hoffmann-La Roche Limited has made $96.0M in payments to 608 healthcare providers, recorded across 9,381 transactions in the CMS Open Payments database. In 2024, the company paid $9.1M. The top product by payment volume is Actemra ($23.7M).
Payments were distributed across 52 medical specialties. The top specialty by payment amount is Hematology & Oncology ($604,401 to 31 doctors).
Payment categories include: Food & Beverage ($76,677), Consulting ($913,272), Research ($94.8M), Travel & Lodging ($141,778).
Hoffmann-La Roche Limited is associated with 2 products in the CMS Open Payments database.